Uropartners
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daneshmand, Siamek
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
325
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
Lesser, Timothy
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
325
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daneshmand, Siamek
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
325
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
Lesser, Timothy
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
325
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27

Download Options